腹腔灌注联合静脉化疗治疗晚期卵巢癌疗效观察

目的:探讨顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌患者的疗效和不良反应。方法:选取晚期卵巢癌患者(Ⅲ-Ⅳ期)70例为研究对象,将患者随机分为顺铂联合多西他赛静脉化疗36例(对照组),以及顺铂腹腔灌注联合多西他赛静脉化疗34例(观察组)。对比分析两组化疗效果以及化疗不良反应。结果:观察组患者总有效率为76.47%,对照组总有效率为50.00%,两组比较差异有统计学意义(P<0.05)。观察组不良反应率为47.06%,毒副反应级别主要为Ⅰ-Ⅱ级。观察组与对照组相比,差异有统计学意义(P<0.05)。各组患者5年生存率无统计学意义(P>0.05);而观察组患者3年生存率为55.88%,显著高于对照组,差异有统计学意义(P<0.05)。观察组平均中位生存时间显著优于对照组,差异有统计学意义(P<0.05)。结论:顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌,较顺铂联合多西他赛静脉化疗疗效好,化疗毒副反应小。

Clinical Effect of Intraperitoneal and Intravenous Chemotherapy for Advanced Ovarian Cancer

Objective:To study the response and toxicities of cisplatin(DDP)intraperitoneal and docetaxel intravenous chemotherapy for advanced ovarian cancer.Methods:Seventy patients with advanced stage ovarian cancer(stageⅢ/Ⅳ)were recruited in the study.The patients were randomly received cisplatin and docetaxel intravenous chemotherapy(control group),or intraperitoneal cisplatin with docetaxel intravenous chemotherapy(trial group).Results:The total effective rate of patients of trial group was 76.47%,which was higher than that of control group(50%)(P<0.05).Trial group also showed lower adverse response rate(47.06%),lower toxicity levels(Ⅰ-Ⅱ grades),higher three-year survival rate(55.88%),and longer survival time than control group(all P<0.05).Conclusion:Intraperitoneal cisplatin and docetaxel intravenous chemotherapy for advanced ovarian cancer showed good efficacy accompanied by less side effects.